Brief: Antengene Says Its U.S. Partner, Karyopharm Therapeutics Inc., Received FDA Approval Of Xpovio As Treatment For Patients With Multiple Myeloma After At Least One Prior Therapy
21/12/2020 24:05
Dec 20 (Reuters) - Antengene Corp Ltd 6996.HK :
* ANTENGENE ANNOUNCES ITS U.S. PARTNER, KARYOPHARM
THERAPEUTICS
INC., HAS RECEIVED FDA APPROVAL OF XPOVIO® (SELINEXOR) AS A
TREATMENT FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST ONE
PRIOR THERAPY
Source text for Eikon: ID:nPn6mKBQQa
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106